Title of article :
Study of the Combination Doxorubicin, Interferon Alpha and High-Dose Tamoxifen Treatment for Advanced Hepatocellular Carcinoma
Author/Authors :
EL HINDAWY, EL SAYED M. Mansoura University - Faculty of Medicine - Department of Clinical Oncology and Nuclear Medicine, Egypt , HEGAZY, MOHAMED Mansoura University - Faculty of Medicine - Department of Surgical Oncology, Egypt , YOUSSEF, TAMER F. Mansoura University - Faculty of Medicine - Department of Surgical Oncology, Egypt , ABO ELFOTOUH, ASHRAF R. Mansoura International Hospital - Department of Gastro-Interology, Egypt
Abstract :
Background: A lot of studies showed that high dose tamoxifen may improve the therapeutic efficiency of doxorubicin in hepatocellular carcinoma (HCC). Interferon a has also been reported to be effective in treatment of HCC. In this study we assess the addition of interferon-a to high dose tamoxifen and doxorubicin could improve the outcome control of advanced HCC. Material and Methods: Eligible patients had non—respectable hepatocellular carcinoma. Large measurable tumor, compensated function, Karnofsky status 60% or more. The patient received oral tamoxifen 40mg/m q.i.d day 1-7; interferon subcutaneous injection 3 mu/m2 every other day for 21 day and 1.V doxorubicin 50mg/m at day 4 repeated every 4 weeks. Results: A total of 45 patients, 40 were eligible, 30 men and 10 women with median age of 50 years. 7 patients had partial remission with a median progression free survival for all patients was 6 month and 1 year survival rate was 11%.
Keywords :
Hepatocellular carcinoma (HCC) , Interferon alpha , Tamoxifen
Journal title :
The Medical Journal of Cairo University
Journal title :
The Medical Journal of Cairo University
